We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App





Abbott Displays Its Life-Changing POC Tests and Diagnostic Tools at MEDLAB Middle East

By LabMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: ID NOW (Photo courtesy of Abbott)
Image: ID NOW (Photo courtesy of Abbott)

At the 2022 edition of MEDLAB Middle East, Abbott (Lake Forest, IL, USA) showcased its portfolio of life-changing diagnostic tools and medical devices for point-of-care testing that help manage patients with COVID-19, diabetes cardiovascular disease and their comorbidities.

Within its COVID-19 test portfolio, Abbott displayed its ID NOW COVID-19 molecular point-of-care platform that combines the benefits of speed and accuracy for the fastest molecular results in the market. The ID NOW COVID-19 test returns positive results in 13 minutes or less to enable immediate clinical decisions during the first patient visit. The easy to use ID NOW platform is designed for near-patient, point-of-care use in a variety of healthcare settings. Abbott highlighted its Panbio COVID-19 IgG/IgM Rapid Test Device, an in vitro diagnostic rapid test for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood, alongside the Panbio COVID-19 Ag Rapid Test Device which can identify potentially contagious patients with or without symptoms in 15 minutes.

Also on display was the Afinion 2 System, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care for physician offices and clinics, eliminating the need to send patients to the lab or spend time tracking down their results. The Afinion 2 System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP, and can reliably transfer test information to a HIS or LIS system. The analyzer and test cartridges have been precision engineered with each test cartridge containing an integrated sample collection device and all necessary reagents for a single test.

At MEDLAB 2022, Abbott demonstrated the i-STAT Family of products for a broad range of clinical settings, including the lightweight, portable and easy to use i-STAT 1 blood analyzer which operates with the advanced technology of i-STAT test cartridges. Together, they create the i-STAT System - a point-of-care testing platform that provides healthcare professionals with diagnostic information when and where it's needed. Abbott also displayed the i-STAT Alinity, an easy-in-use, portable bloody analyzer that delivers real-time, lab-quality diagnostic test results. The i-STAT Alinity is the i-STAT family's most advanced testing solution and features a more intuitive interface that simplifies the testing process even further, allowing for minimal operator training.

Related Links:
Abbott 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Blood Culture Identification Panel
cobas ePlex BCID-GP Panel
New
Nephelometer
F-TC2015

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.